Biotech makes a splash in HK as Ascletis prices IPO
Ascletis Pharma priced its Hong Kong IPO in the middle of expectations on Wednesday, raising HK$3.1bn ($400m) from the city’s inaugural biotechnology offering.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts